Table 3. Serum mesothelin and CA125 before and after 111In-amatuximab.
Patient | Age/Sex | Diagnosis | Mesothelin Levels (nMol/L)* | CA125 (U/mL)^ | ||
---|---|---|---|---|---|---|
Baseline | Day 14 | Baseline | Day 14 | |||
001 | 71/F | Mesothelioma | 4.4 | 6.0 | 86.3 | 188 |
002 | 53/M | Mesothelioma | 11.8 | 15.4 | 1205 | 1447 |
003 | 62/M | Mesothelioma | 3.8 | 5.8 | 5.8 | 9.1 |
004 | 70/M | Mesothelioma | 9.6 | 14.8 | 5.4 | 15.0 |
005 | 54/M | Pancreatic adenocarcinoma | 0.6 | 0.5 | 52 | 143 |
007 | 73/F | Pancreatic adenocarcinoma | 0.6 | 0 | 466 | 1165 |
≥ 1.5 nMol/L is considered abnormally high
Normal range is 1.9–16.3 U/ml